StockMacro
Menu

Adaptive Biotechnologies

$27.93 +98% in 6 monthsMarket cap $4.5B

ADPT on XNAS, Health Care, Adaptive Biotechnologies Corporation, job postings

Measures activity, not value. Not investment advice.

Shares up 71% in a year but quarterly revenue fell 11% and insiders sold $14.7M.

  • BadShort interest rose to 13.5M shares, 1.4 times a year earlier
  • BadLost $70.5M over the last 12 months while revenue grew 18%

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
624
Website
adaptivebiotech.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $83.9M, net income $2.9M.
Quarter to 31 Dec 2021: revenue $37.9M, net income -$61.4MQuarter to 31 Dec 2021: revenue $37.9M, net income -$61.4MQuarter to 31 Mar 2022: revenue $38.6M, net income -$62.7MQuarter to 31 Mar 2022: revenue $38.6M, net income -$62.7MQuarter to 30 Jun 2022: revenue $43.7M, net income -$52.0MQuarter to 30 Jun 2022: revenue $43.7M, net income -$52.0MQuarter to 30 Sep 2022: revenue $47.8M, net income -$45.3MQuarter to 30 Sep 2022: revenue $47.8M, net income -$45.3MQuarter to 31 Dec 2022: revenue $55.2M, net income -$40.1MQuarter to 31 Dec 2022: revenue $55.2M, net income -$40.1MQuarter to 31 Mar 2023: revenue $37.6M, net income -$57.7MQuarter to 31 Mar 2023: revenue $37.6M, net income -$57.7MQuarter to 30 Jun 2023: revenue $48.9M, net income -$47.8MQuarter to 30 Jun 2023: revenue $48.9M, net income -$47.8MQuarter to 30 Sep 2023: revenue $37.9M, net income -$50.3MQuarter to 30 Sep 2023: revenue $37.9M, net income -$50.3MQuarter to 31 Dec 2023: revenue $45.8M, net income -$69.4MQuarter to 31 Dec 2023: revenue $45.8M, net income -$69.4MQuarter to 31 Mar 2024: revenue $41.9M, net income -$47.5MQuarter to 31 Mar 2024: revenue $41.9M, net income -$47.5MQuarter to 30 Jun 2024: revenue $43.2M, net income -$46.2MQuarter to 30 Jun 2024: revenue $43.2M, net income -$46.2MQuarter to 30 Sep 2024: revenue $46.4M, net income -$32.1MQuarter to 30 Sep 2024: revenue $46.4M, net income -$32.1MQuarter to 31 Dec 2024: revenue $47.5M, net income -$33.7MQuarter to 31 Dec 2024: revenue $47.5M, net income -$33.7MQuarter to 31 Mar 2025: revenue $52.4M, net income -$29.9MQuarter to 31 Mar 2025: revenue $52.4M, net income -$29.9MQuarter to 30 Jun 2025: revenue $58.9M, net income -$25.6MQuarter to 30 Jun 2025: revenue $58.9M, net income -$25.6MQuarter to 30 Sep 2025: revenue $94.0M, net income $9.5MQuarter to 30 Sep 2025: revenue $94.0M, net income $9.5MQuarter to 31 Dec 2025: revenue $71.7M, net income -$13.6MQuarter to 31 Dec 2025: revenue $71.7M, net income -$13.6MQuarter to 31 Mar 2026: revenue $70.9M, net income -$20.0MQuarter to 31 Mar 2026: revenue $70.9M, net income -$20.0MQuarter to 30 Jun 2026: revenue $71.6M, net income -$39.8MQuarter to 30 Jun 2026: revenue $71.6M, net income -$39.8MQuarter to 30 Sep 2026: revenue $83.9M, net income $2.9MQuarter to 30 Sep 2026: revenue $83.9M, net income $2.9M
31 Dec 2021RevenueNet incomeNet losstallest bar $94.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$83.9M$2.9M
30 Jun 2026$71.6M-$39.8M
31 Mar 2026$70.9M-$20.0M
31 Dec 2025$71.7M-$13.6M
30 Sep 2025$94.0M$9.5M
30 Jun 2025$58.9M-$25.6M
31 Mar 2025$52.4M-$29.9M
31 Dec 2024$47.5M-$33.7M
30 Sep 2024$46.4M-$32.1M
30 Jun 2024$43.2M-$46.2M
31 Mar 2024$41.9M-$47.5M
31 Dec 2023$45.8M-$69.4M
30 Sep 2023$37.9M-$50.3M
30 Jun 2023$48.9M-$47.8M
31 Mar 2023$37.6M-$57.7M
31 Dec 2022$55.2M-$40.1M
30 Sep 2022$47.8M-$45.3M
30 Jun 2022$43.7M-$52.0M
31 Mar 2022$38.6M-$62.7M
31 Dec 2021$37.9M-$61.4M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $298.0M $252.8M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +18% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$70.5M -$79.6M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.45 -$0.53
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 74.2% 71.8% 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -16.2% -30.9% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -23.7% -31.5% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -37.1% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$8.8M -$62.9M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $299.0M $212.8M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – $131.8M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – -$80.9M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $1.09
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 15.2 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 25.7 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Adaptive BiotechnologiesADPT (this company) $4.5Bloss15.2+18%-23.7%
CRISPR Therapeutics AGCRSP $3.8Bloss151-34%–
Tarsus PharmaceuticalsTARS $3.6Bloss5.3+86%-103%
Relay TherapeuticsRLAY $3.6Bloss–––
Scholar RockSRRK $5.9Blossover 999––
Kodiak SciencesKOD $6.4Bloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$14.7M

bought $0, sold $14.7M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+11%

332 13F filers vs 300

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

166.6M shares held by 13F filers (30 Sep 2026) of 161.9M outstanding (30 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

7.1%

11.5M shares sold short (30 Oct 2026) of 161.9M outstanding (30 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

6.1

11.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-4.3%

12.0M shares sold short in the report before, 11.5M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

41%

41% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 49%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

19

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-11%

$83.9M vs $94.0M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$192K

the 12 months before: $239K

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

15

15 articles in the last 7 days; its usual week has 4 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

3.8×

15 articles in the last 7 days; its usual week has 4.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Short interest 13.5M, 1.4× a year earlier

Price $27.93 on 20 Nov 2026, +71% over 12 months (12-month range $12.41 to $30.26)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $121.5M in the last 12 months (the 12 months before: -$22.8M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.
Revenue per quarter. Revenue $83.9M in the latest quarter, -11% on a year earlier.
Capital spending per quarter. Capital spending $1.9M in the latest quarter, +372% on a year earlier.
Institutional holders (13F filers). 332 13F filers reported holding it in the latest 13F quarter, +30% on a year earlier.
Federal obligations. Federal obligations: $405K published in the last 12 months (none in the 12 months before).
Lobbying spend. Lobbying spend: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
29 Sep 2026Sharp changeShort interest spike: short interest spike, 13.5M vs usual 9.1M (2026-09-15); 1.4x the same period a year earlier
1 Sep 2026Sharp changeShort interest spike: short interest spike, 13.3M vs usual 9.0M (2026-08-14); 1.5x the same period a year earlier
18 Aug 2026Sharp changeShort interest spike: short interest spike, 12.5M vs usual 9.0M (2026-07-31); 1.3x the same period a year earlier
29 Jul 20268-K and other filingsDirector or officer change
29 Jul 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 Jun 20268-K and other filingsA major agreement ended
3 Mar 2026Sharp changeQuarterly revenue change: quarterly revenue change, 71.7M vs usual 46.9M (2025-12-31); 1.5x the same period a year earlier
6 Nov 2025Sharp changeQuarterly revenue change: quarterly revenue change, 94.0M vs usual 46.1M (2025-09-30); 2.0x the same period a year earlier
18 Aug 20258-K and other filingsA major agreement ended
16 Jan 2025Lobbying filinglobbying engagement terminated (ARNOLD & PORTER KAYE SCHOLER LLP)
9 Apr 20248-K and other filingsDirector or officer change
2 Apr 20248-K and other filingsDirector or officer change
2 Apr 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Sep 2023Sharp changeShort interest spike: short interest spike, 10.4M vs usual 6.1M (2023-08-31); 1.5x the same period a year earlier
1 Sep 20238-K and other filingsDirector or officer change
2 Aug 20238-K and other filingsDirector or officer change
3 Jul 20238-K and other filingsDelisting notice or listing transfer
13 Jun 20238-K and other filingsDirector or officer change
11 Apr 20238-K and other filingsDirector or officer change
11 Apr 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Feb 2023Sharp changeQuarterly revenue change: quarterly revenue change, 55.2M vs usual 38.6M (2022-12-31); 1.5x the same period a year earlier
2 Feb 2023Lobbying filinglobbying engagement terminated (PAMELA BRADLEY)
2 Feb 2023Lobbying filingnew lobbying registration (PAMELA BRADLEY)
28 Jun 2022Sharp changeShort interest spike: short interest spike, 7.3M vs usual 4.5M (2022-06-15); 1.8x the same period a year earlier
14 Jun 2022Sharp changeShort interest spike: short interest spike, 6.3M vs usual 4.5M (2022-05-31); 1.5x the same period a year earlier
31 May 2022Sharp changeShort interest spike: short interest spike, 6.9M vs usual 4.5M (2022-05-13); 1.4x the same period a year earlier
23 Mar 2022Lobbying filinglobbying engagement terminated (in-house)
11 Mar 20228-K and other filingsDirector or officer change
15 Feb 20228-K and other filingsDirector or officer change
10 Jan 20228-K and other filingsDirector or officer change
Insider net buying (open market)
Month from 1 Dec 2021: -$760K published
Month from 1 Jan 2022: -$24K published
Month from 1 Mar 2022: -$910K published
Month from 1 Apr 2022: -$11K published
Month from 1 Jul 2022: -$32K published
Month from 1 Aug 2022: -$193K published
Month from 1 Oct 2022: -$23K published
Month from 1 Nov 2022: -$257K published
Month from 1 Jan 2023: -$27K published
Month from 1 Mar 2023: -$911K published
Month from 1 Apr 2023: -$27K published
Month from 1 Jun 2023: -$2.0M published
Month from 1 Aug 2023: -$107K published
Month from 1 Nov 2023: -$1K published
Month from 1 Mar 2024: -$624K published
Month from 1 Aug 2024: -$121K published
Month from 1 Nov 2024: -$1K published
Month from 1 Feb 2025: -$6.4M published
Month from 1 Mar 2025: -$4.3M published
Month from 1 May 2025: -$520K published
Month from 1 Nov 2025: -$11.6M published
Month from 1 Dec 2025: -$9.3M published
Month from 1 Jan 2026: -$3.7M published
Month from 1 Feb 2026: -$3.1M published
Month from 1 Mar 2026: -$32.1M published
Month from 1 Apr 2026: -$8.2M published
Month from 1 May 2026: -$41K published
Month from 1 Jun 2026: -$4.0M published
Month from 1 Jul 2026: -$27.5M published
Month from 1 Aug 2026: -$19.1M published
Month from 1 Sep 2026: -$3.3M published
Month from 1 Oct 2026: -$7.5M published
Month from 1 Nov 2026: -$3.7M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 4 published
Quarter from 1 Apr 2022: 4 published
Quarter from 1 Jul 2022: 2 published
Quarter from 1 Oct 2022: 4 published
Quarter from 1 Jan 2023: 2 published
Quarter from 1 Apr 2023: 1 published
Quarter from 1 Jul 2023: 2 published
Quarter from 1 Oct 2024: 3 published
Quarter from 1 Apr 2025: 1 published
Quarter from 1 Jul 2025: 2 published
Revenue per quarter
Quarter ended 31 Dec 2021: $37.9M, +26% on a year earlier; public on 16 Feb 2022
Quarter ended 31 Mar 2022: $38.6M, +0.5% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $43.7M, +13% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $47.8M, +21% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $55.2M, +46% on a year earlier; public on 15 Feb 2023
Quarter ended 31 Mar 2023: $37.6M, -2.5% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $48.9M, +12% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $37.9M, -21% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $45.8M, -17% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $41.9M, +11% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $43.2M, -12% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $46.4M, +22% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $47.5M, +3.7% on a year earlier; public on 4 Mar 2025
Quarter ended 31 Mar 2025: $52.4M, +25% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $58.9M, +36% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $94.0M, +102% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $71.7M, +51% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $70.9M, +35% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $71.6M, +22% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $83.9M, -11% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $9.2M, -1.3% on a year earlier; public on 16 Feb 2022
Quarter ended 31 Mar 2022: $3.1M, -81% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $5.3M, -76% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $5.4M, -63% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $2.5M, -73% on a year earlier; public on 15 Feb 2023
Quarter ended 31 Mar 2023: $2.9M, -5.0% on a year earlier; public on 4 May 2023
Quarter ended 30 Jun 2023: $3.7M, -30% on a year earlier; public on 3 Aug 2023
Quarter ended 30 Sep 2023: $2.8M, -49% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $1.3M, -49% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $1.5M, -48% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $1.7M, -53% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $344K, -88% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $80K, -94% on a year earlier; public on 4 Mar 2025
Quarter ended 31 Mar 2025: $1.3M, -17% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $655K, -62% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $409K, +19% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $636K, +695% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $796K, -37% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $1.2M, +81% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $1.9M, +372% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 190; public on 14 Feb 2022
31 Mar 2022 report: 208; public on 16 May 2022
30 Jun 2022 report: 198; public on 15 Aug 2022
30 Sep 2022 report: 207; public on 14 Nov 2022
31 Dec 2022 report: 202; public on 14 Feb 2023
31 Mar 2023 report: 207; public on 15 May 2023
30 Jun 2023 report: 194; public on 14 Aug 2023
30 Sep 2023 report: 177; public on 14 Nov 2023
31 Dec 2023 report: 188; public on 14 Feb 2024
31 Mar 2024 report: 179; public on 15 May 2024
30 Jun 2024 report: 164; public on 14 Aug 2024
30 Sep 2024 report: 181; public on 14 Nov 2024
31 Dec 2024 report: 205; public on 14 Feb 2025
31 Mar 2025 report: 220; public on 15 May 2025
30 Jun 2025 report: 232; public on 14 Aug 2025
30 Sep 2025 report: 255; public on 14 Nov 2025
31 Dec 2025 report: 278; public on 17 Feb 2026
31 Mar 2026 report: 289; public on 15 May 2026
30 Jun 2026 report: 300; public on 14 Aug 2026
30 Sep 2026 report: 332; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $200 published
Month from 1 Jan 2022: $32K published
Month from 1 Apr 2022: $52K published
Month from 1 Jun 2022: -$6K published
Month from 1 Jul 2022: $182K published
Month from 1 Aug 2022: $48K published
Month from 1 Sep 2022: $24K published
Month from 1 Nov 2022: $398K published
Month from 1 Jan 2023: $112K published
Month from 1 Mar 2023: -$15K published
Month from 1 Jun 2023: $166K published
Month from 1 Jul 2023: -$9K published
Month from 1 Sep 2023: $12K published
Month from 1 Nov 2023: $90K published
Month from 1 Feb 2024: $13K published
Month from 1 Mar 2024: $13K published
Month from 1 Apr 2024: $166K published
Month from 1 May 2024: $72K published
Month from 1 Sep 2024: $272K published
Month from 1 Oct 2024: $76K published
Month from 1 Nov 2024: $0 published
Month from 1 Dec 2024: -$306K published
Month from 1 Apr 2025: $95K published
Month from 1 May 2025: $45K published
Month from 1 Jun 2025: $134K published
Month from 1 Oct 2025: -$154K published
Month from 1 Nov 2025: $0 published
Month from 1 Jan 2026: $244K published
Month from 1 Feb 2026: $0 published
Month from 1 Apr 2026: $0 published
Month from 1 May 2026: $172K published
Month from 1 Jun 2026: $35K published
Month from 1 Jul 2026: $0 published
Month from 1 Sep 2026: -$84K published
Month from 1 Oct 2026: $39K published
Lobbying spend
Quarter from 1 Jan 2022: $190K published
Quarter from 1 Oct 2022: $80K published
Quarter from 1 Jan 2023: $390K published
Quarter from 1 Apr 2023: $80K published
Quarter from 1 Jul 2023: $60K published
Quarter from 1 Oct 2023: $30K published
Quarter from 1 Jan 2024: $30K published

What is unusual now

  • Made public in the last 90 days: it had 13.5M shares sold short in the 15 Sep 2026 report, 1.4× the same report last year; it also had 13.3M shares sold short in the 14 Aug 2026 report, 1.5× the same report last year.
  • Short interest spike: had 13.5M shares sold short in the 15 Sep 2026 report, 1.4× the same report last year Public on 25 Sep 2026.
  • Insider net buying (open market): Insiders sold a net $121.5M in the last 12 months (the 12 months before: -$22.8M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 17 sales, $14.7M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
13 Nov 2026Julie RubinsteinPresident and COOSellplanned in advance (10b5-1); after exercising options35,228$29.73$1.0MForm 4
13 Nov 2026Susan BobulskyChief Commercial Officer, MRDSellplanned in advance (10b5-1)1,875$32.00$60KForm 4
10 Nov 2026Julie RubinsteinPresident and COOSellplanned in advance (10b5-1); after exercising options23,762$29.82$709KForm 4
6 Nov 2026Julie RubinsteinPresident and COOSellplanned in advance (10b5-1); after exercising options35,643$26.78$954KForm 4
3 Nov 2026Julie RubinsteinPresident and COOSellplanned in advance (10b5-1); after exercising options35,643$26.06$929KForm 4
29 Oct 2026Julie RubinsteinPresident and COOSellplanned in advance (10b5-1); after exercising options35,643$28.00$998KForm 4
26 Oct 2026Julie RubinsteinPresident and COOSellplanned in advance (10b5-1); after exercising options35,643$25.18$897KForm 4
21 Oct 2026Julie RubinsteinPresident and COOSellplanned in advance (10b5-1); after exercising options35,643$24.66$879KForm 4

332 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 60 opened a position, 29 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Viking Global Investors LP30.0M18.5%$866.8MNo change
BlackRock, Inc.15.3M9.45%$442.2M+163K+1.1%
Vanguard Capital Management LLC6.4M3.98%$186.0M+32K+0.5%
D. E. Shaw & Co., Inc.6.4M3.94%$184.2M+1.7M+38%
T. Rowe Price Associates Inc5.7M3.52%+3.0M+114%
Vanguard Portfolio Management LLC5.2M3.24%$151.4M-237K-4.3%
Wellington Management Group LLP4.7M2.93%$137.2M-1.2M-20%
Driehaus Capital Management LLC4.7M2.91%$136.0M+2.2M+86%
Geode Capital Management, LLC3.7M2.30%$107.5M+79K+2.2%
T. Rowe Price Investment Management, Inc.3.6M2.22%+1.8M+102%

Company events

All 31 company events

In 12 months: 1 major agreement, 1 agreement ended, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
29 Jul 2026Director or officer change8-K
22 Jun 2026Signed a major agreement; A major agreement endedSame filing: took on new debt, sold shares privately8-K
18 Aug 2025A major agreement ended8-K
9 Apr 2024Director or officer change8-K
2 Apr 2024Director or officer change8-K
1 Sep 2023Director or officer change8-K
2 Aug 2023Director or officer change8-K
3 Jul 2023Delisting notice or listing transfer8-K

19 open postings; careers site tracked since 20 Nov 2026. Most in Legal, policy & compliance 21%, Operations & administration 21%, Sales & business development 21%, ML / AI 11%.

PostedJobLocation
20 Nov 2026Scientist II, ValidationResearch & scienceSeattle
19 Nov 2026Account Operations Manager (Northeast)Operations & administrationRemote (WFH)
19 Nov 2026Clinical Lab Technologist I/II/IIIOperations & administrationSeattle
19 Nov 2026Revenue Operations SpecialistSales & business developmentRemote (WFH)
19 Nov 2026Medicare Reimbursement LeadOperations & administrationRemote (WFH)
6 Nov 2026Account Manager (New Mexico)Sales & business developmentRemote (WFH)
22 Oct 2026Senior Talent Development ManagerPeople & recruitingSeattle
22 Oct 2026Clinical Affairs ManagerLegal, policy & complianceRemote (WFH)

Reported lobbying spend: $30K in Q4 2023, $30K in Q3 2023. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Dec 2024EndedArnold & Porter Kaye Scholer LLPfor Adaptive BiotechnologiesNot statedFiling
8 Apr 2022EndedPamela Bradleyfor Adaptive Biotechnologies Corp2023 appropriations requests for NIH for T cell research in COVID19 and other disease areas; HR4128 and S2209 The VALID Act. Provisions related to first of a kind assaysMEDFiling
23 Mar 2022EndedAdaptive Biotechnologiesits own lobbyistsIssues related to T cells, COVID testing, pandemic preparedness and immune medicine H.R. 6102 and S. 3404, The Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020, all provisions H.R. 5745, COVID-19 Access to Testing and Support for Immune Response Research Act of 2021 S. 3062 Depar; H.R. 1946 and S. 1873- Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021 H.R. 5745, COVID-19 Access to Testing and Support for Immune Response Research Act of 2021Health issues, Medicare/MedicaidFiling
9 Mar 2022NewPamela Bradleyfor Adaptive Biotechnologies CorpH.R. 1428, The VALID Act NIH AppropriationsHealth issues, MED, Medicare/MedicaidFiling
1 Oct 2020NewAdaptive Biotechnologiesits own lobbyistsH.R.6102 and S.3404, Verifying Accurate Leading-edge IVCT Development Act of 2020, all provisionsHealth issues, Medicare/Medicaid, MEDFiling
1 May 2020NewArnold & Porter Kaye Scholer LLPfor Adaptive BiotechnologiesSupport for immune-driven biotechnologies platformsMedicare/Medicaid, Health issuesFiling
19 Nov 2015EndedMcdermott+ LLCfor Adaptive BiotechnologiesNot statedFiling
1 Jan 2015NewMcdermott+ LLCfor Adaptive BiotechnologiesFDA regulation of laboratory-developed tests. Medicare reimbursement for laboratory-developed tests.Health issues, Medicare/Medicaid, MEDFiling

The 5 newest of 184 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 25 Sep 2026Short interest and volume change

    had 13.5M shares sold short in the 15 Sep 2026 report, 1.4× the same report last year.

    Same report last year: 9.3M; its normal report is 9.1M.

    See the evidence
    This period
    13.5M (the 15 Sep 2026 report)
    Normal report (median of 24 earlier)
    9.1M
    Typical spread (median absolute deviation)
    558K
    How far from its usual level
    +4.8
    Same report last year
    9.3M
    History used
    2,619 days
    2025-09-15: 9.3M2025-09-30: 9.6M2025-10-15: 9.0M2025-10-31: 9.0M2025-11-14: 10.4M2025-11-28: 10.4M2025-12-15: 9.7M2025-12-31: 8.8M2026-01-15: 9.0M2026-01-30: 9.0M2026-02-13: 9.2M2026-02-27: 8.9M2026-03-13: 9.2M2026-03-31: 8.6M2026-04-15: 8.6M2026-04-30: 8.4M2026-05-15: 8.9M2026-05-29: 8.2M2026-06-15: 7.6M2026-06-30: 11.4M2026-07-15: 11.4M2026-07-31: 12.5M2026-08-14: 13.3M2026-08-31: 11.7M2026-09-15: 13.5M
    the 15 Sep 2026 report24 earlier reportsnormal: 9.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  2. 26 Aug 2026Short interest and volume change

    had 13.3M shares sold short in the 14 Aug 2026 report, 1.5× the same report last year.

    Same report last year: 8.9M; its normal report is 9.0M.

    See the evidence
    This period
    13.3M (the 14 Aug 2026 report)
    Normal report (median of 24 earlier)
    9.0M
    Typical spread (median absolute deviation)
    469K
    How far from its usual level
    +4.8
    Same report last year
    8.9M
    History used
    2,587 days
    2025-08-15: 8.9M2025-08-29: 8.4M2025-09-15: 9.3M2025-09-30: 9.6M2025-10-15: 9.0M2025-10-31: 9.0M2025-11-14: 10.4M2025-11-28: 10.4M2025-12-15: 9.7M2025-12-31: 8.8M2026-01-15: 9.0M2026-01-30: 9.0M2026-02-13: 9.2M2026-02-27: 8.9M2026-03-13: 9.2M2026-03-31: 8.6M2026-04-15: 8.6M2026-04-30: 8.4M2026-05-15: 8.9M2026-05-29: 8.2M2026-06-15: 7.6M2026-06-30: 11.4M2026-07-15: 11.4M2026-07-31: 12.5M2026-08-14: 13.3M
    the 14 Aug 2026 report24 earlier reportsnormal: 9.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  3. 12 Aug 2026Short interest and volume change

    had 12.5M shares sold short in the 31 Jul 2026 report, 1.3× the same report last year.

    Same report last year: 9.9M; its normal report is 9.0M.

    See the evidence
    This period
    12.5M (the 31 Jul 2026 report)
    Normal report (median of 24 earlier)
    9.0M
    Typical spread (median absolute deviation)
    469K
    How far from its usual level
    +3.8
    Same report last year
    9.9M
    History used
    2,573 days
    2025-07-31: 9.9M2025-08-15: 8.9M2025-08-29: 8.4M2025-09-15: 9.3M2025-09-30: 9.6M2025-10-15: 9.0M2025-10-31: 9.0M2025-11-14: 10.4M2025-11-28: 10.4M2025-12-15: 9.7M2025-12-31: 8.8M2026-01-15: 9.0M2026-01-30: 9.0M2026-02-13: 9.2M2026-02-27: 8.9M2026-03-13: 9.2M2026-03-31: 8.6M2026-04-15: 8.6M2026-04-30: 8.4M2026-05-15: 8.9M2026-05-29: 8.2M2026-06-15: 7.6M2026-06-30: 11.4M2026-07-15: 11.4M2026-07-31: 12.5M
    the 31 Jul 2026 report24 earlier reportsnormal: 9.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 29 Jul 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 29 Jul 2026Filings record

    Director or officer change

  6. 22 Jun 2026Filings record

    A major agreement ended

  7. 3 Mar 2026Financials change

    reported revenue of $71.7M for the quarter ended 31 Dec 2025, 1.5× the same quarter last year.

    Same quarter last year: $47.5M; its normal quarter is $46.9M.

    See the evidence
    This period
    $71.7M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $46.9M
    Typical spread (median absolute deviation)
    $4.4M
    How far from its usual level
    +3.8
    Same quarter last year
    $47.5M
    History used
    2,741 days
    2023-12-31: $45.8M2024-03-31: $41.9M2024-06-30: $43.2M2024-09-30: $46.4M2024-12-31: $47.5M2025-03-31: $52.4M2025-06-30: $58.9M2025-09-30: $94.0M2025-12-31: $71.7M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $46.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  8. 6 Nov 2025Financials change

    reported revenue of $94.0M for the quarter ended 30 Sep 2025, 2.0× the same quarter last year.

    Same quarter last year: $46.4M; its normal quarter is $46.1M.

    See the evidence
    This period
    $94.0M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $46.1M
    Typical spread (median absolute deviation)
    $3.6M
    How far from its usual level
    +9.0
    Same quarter last year
    $46.4M
    History used
    2,649 days
    2023-09-30: $37.9M2023-12-31: $45.8M2024-03-31: $41.9M2024-06-30: $43.2M2024-09-30: $46.4M2024-12-31: $47.5M2025-03-31: $52.4M2025-06-30: $58.9M2025-09-30: $94.0M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $46.1M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  9. 18 Aug 2025Filings record

    A major agreement ended

  10. 16 Jan 2025Lobbying record

    ADAPTIVE BIOTECHNOLOGIES: lobbying engagement terminated (ARNOLD & PORTER KAYE SCHOLER LLP) (dated 31 Dec 2024)

  11. 9 Apr 2024Filings record

    Director or officer change

  12. 2 Apr 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 2 Apr 2024Filings record

    Director or officer change

  14. 13 Sep 2023Short interest and volume change

    had 10.4M shares sold short in the 31 Aug 2023 report, 1.5× the same report last year.

    Same report last year: 6.9M; its normal report is 6.1M.

    See the evidence
    This period
    10.4M (the 31 Aug 2023 report)
    Normal report (median of 24 earlier)
    6.1M
    Typical spread (median absolute deviation)
    783K
    How far from its usual level
    +3.7
    Same report last year
    6.9M
    History used
    1,508 days
    2022-08-31: 6.9M2022-09-15: 6.2M2022-09-30: 6.5M2022-10-14: 6.1M2022-10-31: 6.0M2022-11-15: 5.1M2022-11-30: 5.3M2022-12-15: 4.7M2022-12-30: 5.9M2023-01-13: 5.4M2023-01-31: 4.8M2023-02-15: 4.4M2023-02-28: 4.9M2023-03-15: 5.3M2023-03-31: 6.1M2023-04-14: 5.4M2023-04-28: 6.1M2023-05-15: 6.6M2023-05-31: 7.3M2023-06-15: 8.1M2023-06-30: 8.0M2023-07-14: 9.0M2023-07-31: 9.5M2023-08-15: 10.1M2023-08-31: 10.4M
    the 31 Aug 2023 report24 earlier reportsnormal: 6.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 1 Sep 2023Filings record

    Director or officer change

  16. 2 Aug 2023Filings record

    Director or officer change

  17. 3 Jul 2023Filings record

    Delisting notice or listing transfer

  18. 13 Jun 2023Filings record

    Director or officer change

  19. 11 Apr 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 11 Apr 2023Filings record

    Director or officer change

  21. 21 Feb 2023Financials change

    reported revenue of $55.2M for the quarter ended 31 Dec 2022, 1.5× the same quarter last year.

    Same quarter last year: $37.9M; its normal quarter is $38.6M.

    See the evidence
    This period
    $55.2M (the quarter ended 31 Dec 2022)
    Normal quarter (median of 8 earlier)
    $38.6M
    Typical spread (median absolute deviation)
    $768K
    How far from its usual level
    +4.3
    Same quarter last year
    $37.9M
    History used
    1,645 days
    2020-12-31: $30.2M2021-03-31: $38.4M2021-06-30: $38.5M2021-09-30: $39.5M2021-12-31: $37.9M2022-03-31: $38.6M2022-06-30: $43.7M2022-09-30: $47.8M2022-12-31: $55.2M
    the quarter ended 31 Dec 20228 earlier quartersnormal: $38.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  22. 2 Feb 2023Lobbying record

    ADAPTIVE BIOTECHNOLOGIES CORP: lobbying engagement terminated (PAMELA BRADLEY) (dated 8 Apr 2022)

  23. 2 Feb 2023Lobbying record

    ADAPTIVE BIOTECHNOLOGIES CORP: new lobbying registration (PAMELA BRADLEY) (dated 9 Mar 2022)

  24. 28 Jun 2022Short interest and volume change

    had 7.3M shares sold short in the 15 Jun 2022 report, 1.8× the same report last year.

    Same report last year: 4.2M; its normal report is 4.5M.

    See the evidence
    This period
    7.3M (the 15 Jun 2022 report)
    Normal report (median of 24 earlier)
    4.5M
    Typical spread (median absolute deviation)
    363K
    How far from its usual level
    +5.3
    Same report last year
    4.2M
    History used
    1,066 days
    2021-05-28: 4.4M2021-06-15: 4.2M2021-06-30: 4.7M2021-07-15: 4.6M2021-07-30: 4.8M2021-08-13: 4.4M2021-08-31: 4.0M2021-09-15: 4.2M2021-09-30: 4.4M2021-10-15: 4.3M2021-10-29: 4.2M2021-11-15: 3.8M2021-11-30: 3.7M2021-12-15: 4.1M2022-01-14: 4.3M2022-01-31: 5.2M2022-02-15: 5.7M2022-02-28: 5.4M2022-03-15: 5.4M2022-03-31: 4.8M2022-04-14: 5.3M2022-04-29: 5.2M2022-05-13: 6.9M2022-05-31: 6.3M2022-06-15: 7.3M
    the 15 Jun 2022 report24 earlier reportsnormal: 4.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 10 Jun 2022Short interest and volume change

    had 6.3M shares sold short in the 31 May 2022 report, 1.5× the same report last year.

    Same report last year: 4.4M; its normal report is 4.5M.

    See the evidence
    This period
    6.3M (the 31 May 2022 report)
    Normal report (median of 24 earlier)
    4.5M
    Typical spread (median absolute deviation)
    328K
    How far from its usual level
    +3.8
    Same report last year
    4.4M
    History used
    1,051 days
    2021-05-14: 4.8M2021-05-28: 4.4M2021-06-15: 4.2M2021-06-30: 4.7M2021-07-15: 4.6M2021-07-30: 4.8M2021-08-13: 4.4M2021-08-31: 4.0M2021-09-15: 4.2M2021-09-30: 4.4M2021-10-15: 4.3M2021-10-29: 4.2M2021-11-15: 3.8M2021-11-30: 3.7M2021-12-15: 4.1M2022-01-14: 4.3M2022-01-31: 5.2M2022-02-15: 5.7M2022-02-28: 5.4M2022-03-15: 5.4M2022-03-31: 4.8M2022-04-14: 5.3M2022-04-29: 5.2M2022-05-13: 6.9M2022-05-31: 6.3M
    the 31 May 2022 report24 earlier reportsnormal: 4.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 25 May 2022Short interest and volume change

    had 6.9M shares sold short in the 13 May 2022 report, 1.4× the same report last year.

    Same report last year: 4.8M; its normal report is 4.5M.

    See the evidence
    This period
    6.9M (the 13 May 2022 report)
    Normal report (median of 24 earlier)
    4.5M
    Typical spread (median absolute deviation)
    298K
    How far from its usual level
    +5.4
    Same report last year
    4.8M
    History used
    1,033 days
    2021-04-30: 4.8M2021-05-14: 4.8M2021-05-28: 4.4M2021-06-15: 4.2M2021-06-30: 4.7M2021-07-15: 4.6M2021-07-30: 4.8M2021-08-13: 4.4M2021-08-31: 4.0M2021-09-15: 4.2M2021-09-30: 4.4M2021-10-15: 4.3M2021-10-29: 4.2M2021-11-15: 3.8M2021-11-30: 3.7M2021-12-15: 4.1M2022-01-14: 4.3M2022-01-31: 5.2M2022-02-15: 5.7M2022-02-28: 5.4M2022-03-15: 5.4M2022-03-31: 4.8M2022-04-14: 5.3M2022-04-29: 5.2M2022-05-13: 6.9M
    the 13 May 2022 report24 earlier reportsnormal: 4.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 23 Mar 2022Lobbying record

    ADAPTIVE BIOTECHNOLOGIES: lobbying engagement terminated (in-house)

  28. 11 Mar 2022Filings record

    Director or officer change

  29. 15 Feb 2022Filings record

    Director or officer change

  30. 10 Jan 2022Filings record

    Director or officer change

  31. 9 Nov 2021Financials change

    spent $14.6M on capital projects in the quarter ended 30 Sep 2021, 3.5× the same quarter last year.

    Same quarter last year: $4.2M; its normal quarter is $3.8M.

    See the evidence
    This period
    $14.6M (the quarter ended 30 Sep 2021)
    Normal quarter (median of 8 earlier)
    $3.8M
    Typical spread (median absolute deviation)
    $1.5M
    How far from its usual level
    +4.9
    Same quarter last year
    $4.2M
    History used
    1,096 days
    2019-09-30: $3.4M2019-12-31: $2.4M2020-03-31: $3.0M2020-06-30: $2.3M2020-09-30: $4.2M2020-12-31: $9.4M2021-03-31: $15.8M2021-06-30: $22.0M2021-09-30: $14.6M
    the quarter ended 30 Sep 20218 earlier quartersnormal: $3.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  32. 3 Nov 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  33. 3 Nov 2021Filings record

    Director or officer change

  34. 10 Aug 2021Financials change

    spent $22.0M on capital projects in the quarter ended 30 Jun 2021, 9.7× the same quarter last year.

    Same quarter last year: $2.3M; its normal quarter is $3.2M.

    See the evidence
    This period
    $22.0M (the quarter ended 30 Jun 2021)
    Normal quarter (median of 8 earlier)
    $3.2M
    Typical spread (median absolute deviation)
    $972K
    How far from its usual level
    +13.1
    Same quarter last year
    $2.3M
    History used
    1,004 days
    2019-06-30: $1.5M2019-09-30: $3.4M2019-12-31: $2.4M2020-03-31: $3.0M2020-06-30: $2.3M2020-09-30: $4.2M2020-12-31: $9.4M2021-03-31: $15.8M2021-06-30: $22.0M
    the quarter ended 30 Jun 20218 earlier quartersnormal: $3.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  35. 11 May 2021Financials change

    reported revenue of $38.4M for the quarter ended 31 Mar 2021, 1.8× the same quarter last year.

    Same quarter last year: $20.9M; its normal quarter is $23.2M.

    See the evidence
    This period
    $38.4M (the quarter ended 31 Mar 2021)
    Normal quarter (median of 8 earlier)
    $23.2M
    Typical spread (median absolute deviation)
    $2.6M
    How far from its usual level
    +4.0
    Same quarter last year
    $20.9M
    History used
    1,005 days
    2019-03-31: $12.7M2019-06-30: $22.1M2019-09-30: $26.1M2019-12-31: $24.2M2020-03-31: $20.9M2020-06-30: $21.0M2020-09-30: $26.3M2020-12-31: $30.2M2021-03-31: $38.4M
    the quarter ended 31 Mar 20218 earlier quartersnormal: $23.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  36. 11 May 2021Financials change

    spent $15.8M on capital projects in the quarter ended 31 Mar 2021, 5.3× the same quarter last year.

    Same quarter last year: $3.0M; its normal quarter is $3.2M.

    See the evidence
    This period
    $15.8M (the quarter ended 31 Mar 2021)
    Normal quarter (median of 8 earlier)
    $3.2M
    Typical spread (median absolute deviation)
    $857K
    How far from its usual level
    +10.0
    Same quarter last year
    $3.0M
    History used
    913 days
    2019-03-31: $3.8M2019-06-30: $1.5M2019-09-30: $3.4M2019-12-31: $2.4M2020-03-31: $3.0M2020-06-30: $2.3M2020-09-30: $4.2M2020-12-31: $9.4M2021-03-31: $15.8M
    the quarter ended 31 Mar 20218 earlier quartersnormal: $3.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  37. 17 Mar 2021Filings record

    Director or officer change

  38. 5 Mar 2021Filings record

    Director or officer change

  39. 2 Mar 2021Financials change

    spent $9.4M on capital projects in the quarter ended 31 Dec 2020, 3.9× the same quarter last year.

    Same quarter last year: $2.4M; its normal quarter is $2.7M.

    See the evidence
    This period
    $9.4M (the quarter ended 31 Dec 2020)
    Normal quarter (median of 8 earlier)
    $2.7M
    Typical spread (median absolute deviation)
    $584K
    How far from its usual level
    +6.6
    Same quarter last year
    $2.4M
    History used
    823 days
    2018-12-31: $2.5M2019-03-31: $3.8M2019-06-30: $1.5M2019-09-30: $3.4M2019-12-31: $2.4M2020-03-31: $3.0M2020-06-30: $2.3M2020-09-30: $4.2M2020-12-31: $9.4M
    the quarter ended 31 Dec 20208 earlier quartersnormal: $2.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  40. 27 Jan 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

Showing the newest 40 of 66 entries; narrow the window or the kind of data to see older ones.

Not listed: 492 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001478320
Ticker
ADPT
Domain
adaptivebiotech.com
Employer name
Adaptive Biotechnologies Corporation (1 unverified)
Hq location
WA|SEATTLE|98109 (1 unverified)
Lobbying client
adaptive biotechnologies
Name
Adaptive Biotechnologies Corporation, Adaptive TCR Corp
Uei
DMW5BNQ331K9
Wikidata
Q30283420
  • DOL H-1B labor condition applications and PERM certifications145 data points21 Sep 2020 to 20 Jul 2026
  • Federal lobbying disclosures (LDA)8 records, 62 data points1 Jan 2015 to 31 Dec 2024
  • SEC Form 13F institutional holdings1 record, 270 data points30 Jun 2019 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)108 records30 May 2019 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)620 data points31 Dec 2016 to 30 Oct 2026
  • SEC Form 4 insider transactions414 records, 952 data points2 Jul 2019 to 13 Nov 2026
  • FINRA short interest (twice monthly)524 data points15 Jul 2019 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3724 data points27 Jun 2019 to 20 Nov 2026
  • USASpending.gov federal awards511 data points27 Jul 2010 to 25 Sep 2026